Literature DB >> 10593712

Determination of rifampicin, isoniazid and pyrazinamide by high performance liquid chromatography after their simultaneous extraction from plasma.

P J Smith1, J van Dyk, A Fredericks.   

Abstract

SETTING: Isoniazid (INH), rifampicin (RIF), and pyrazinamide (PZA) are first-line antituberculosis drugs. Due to difficulties in producing effective combined formulations of these three drugs, the bioavailability of new combination formulations needs to be assessed prior to registration.
OBJECTIVE: To develop a rapid, simple and sensitive high performance liquid chromatography (HPLC) assay method suitable for assaying RIF, INH and PZA in large numbers of plasma samples generated in bioavailability studies.
METHOD: RIF, desacetyl-rifampicin (DRIF), INH and PZA were extracted simultaneously from plasma using a solid phase extraction column. RIF and DRIF were quantitated by HPLC using an 80% acetonitrile/0.1% trifluoroacetic acid (TFA) mobile phase and a C8 reversed phase column. INH and PZA were also quantitated on a C8 reversed phase column, but a 3% acetonitrile/0.6% TFA mobile phase was used.
RESULTS: Mean recovery of RIF, DRIF and PZA from plasma was well over 90%, and over 70% for INH. Calibration graphs were linear for all the drugs in their therapeutic range. Correlation coefficients were all above 0.9995, and between- and within-run coefficients of variation below 10%.
CONCLUSION: A simple, accurate, sensitive and cost effective assay for first-line antituberculosis drugs has been developed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10593712

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  11 in total

1.  Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients.

Authors:  Justin J Wilkins; Grant Langdon; Helen McIlleron; Goonaseelan Colin Pillai; Peter J Smith; Ulrika S H Simonsson
Journal:  Eur J Clin Pharmacol       Date:  2006-05-10       Impact factor: 2.953

2.  Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption.

Authors:  Justin J Wilkins; Radojka M Savic; Mats O Karlsson; Grant Langdon; Helen McIlleron; Goonaseelan Pillai; Peter J Smith; Ulrika S H Simonsson
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

3.  Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.

Authors:  Helen McIlleron; Peter Wash; André Burger; Jennifer Norman; Peter I Folb; Pete Smith
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

4.  Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.

Authors:  S Thee; J A Seddon; P R Donald; H I Seifart; C J Werely; A C Hesseling; B Rosenkranz; S Roll; K Magdorf; H S Schaaf
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

5.  Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients.

Authors:  Justin J Wilkins; Grant Langdon; Helen McIlleron; Goonaseelan Pillai; Peter J Smith; Ulrika S H Simonsson
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

6.  Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for determination of isoniazid in human plasma.

Authors:  Liusheng Huang; Florence Marzan; Anura L Jayewardene; Patricia S Lizak; Xiaohua Li; Francesca T Aweeka
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-12-24       Impact factor: 3.205

7.  Quantification of rifampicin in human plasma and cerebrospinal fluid by a highly sensitive and rapid liquid chromatographic-tandem mass spectrometric method.

Authors:  Abhishek Srivastava; David Waterhouse; Alison Ardrey; Stephen A Ward
Journal:  J Pharm Biomed Anal       Date:  2012-06-01       Impact factor: 3.935

8.  Theoretically Guided Analytical Method Development and Validation for the Estimation of Rifampicin in a Mixture of Isoniazid and Pyrazinamide by UV Spectrophotometer.

Authors:  Mohammad F Khan; Shamima A Rita; Md Shahidulla Kayser; Md Shariful Islam; Sharmeen Asad; Ridwan Bin Rashid; Md Abdul Bari; Muhammed M Rahman; D A Anwar Al Aman; Nurul I Setu; Rebecca Banoo; Mohammad A Rashid
Journal:  Front Chem       Date:  2017-04-28       Impact factor: 5.221

9.  Simultaneous Spectrophotometric Determination of Rifampicin, Isoniazid and Pyrazinamide in a Single Step.

Authors:  Karim Asadpour-Zeynali; Elhameh Saeb
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

10.  Development and validation of liquid chromatography-mass spectrometry method for the estimation of rifampicin in plasma.

Authors:  J S Patil; Sarasija Suresh; A R Sureshbabu; M S Rajesh
Journal:  Indian J Pharm Sci       Date:  2011-09       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.